Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening
Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types
Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.